Onconetix, Inc. filed a Form S-1 Registration Statement on November 4, 2025, registering the resale of 22,071,891 shares of Common Stock, primarily derived from recent private placements including Series D (Sept 2025), Series E (Oct 2025), and prior institutional funding. The estimated maximum offering value for these shares is approximately $68.86 million. The registration covers securities that will cause substantial dilution upon conversion or exercise.
The company has shifted its strategic focus. While positioned as a commercial-stage biotech covering oncology and men’s health, it has **a
...